bcsinnovations

In a seminar delivered at the Australian Institute for Bioengineering and Nanotechnology (AIBN) in Brisbane last Month, a team of seasoned experts from BCS Innovations gave presentations on three key areas involving the commercialisation of public sector research.

Dr Peter Spencer, the Commercialisation Manager at BCS Innovations, gave a presentation entitled “Product or Perish”. In his talk, Dr Spencer drew on his previous experience as a corporate director at Johnson & Johnson, using real world examples to explain why inventors should try and move from a platform technology to a distinct product in order to successfully commercialise their concept.

David Bull, the CEO of BCS Innovations, gave a talk on “Turning Platforms into Products”. In his seminar, David explained some of the common traps which inventors fall into, such as failing to control feature creep, and how to mitigate such risks during the product development lifecycle.

Neil Covey, a business strategist at BCS innovations, gave an insightful account on the basics of negotiating license deals. He also gave some humorous, but practical tips on how to identify and manage the condition known as “Mad Inventor Syndrome”. Neil's recent experience in such negotiations together with his previous role as the marketing and business development manager for Bayer Pharmaceuticals allowed him to weave useful, practical experience into his seminar.

The representatives of BCS who spoke at this event are all members of BCS's Technical Advisory Board. The board was specifically established to assist BCS in supporting our clients in navigating the often-difficult pathway from R&D to the commercialisation stage. In this way BCS can offer clients a full service to optimise project development in a way that leads the R&D efforts on the best path to market.  This market specific approach also has a significant impact on the best use of available budgets.